FGF21 and hepatocellular carcinoma: This result might be consistent with our finding that a high FGF21 level is associated with poor prognosis in patients with unresectable HCC who were treated with an anti-PDL-1 combination therapy of atezolizumab/bevacizumab, which does not affect FGF21-mediated signalling.